Neuro-oncology advances最新文献

{"title":"In situ optical feedback in brain tumor biopsy: A multiparametric analysis.","authors":"Elisabeth Klint, Johan Richter, Peter Milos, Martin Hallbeck, Karin Wårdell","doi":"10.1093/noajnl/vdae175","DOIUrl":"10.1093/noajnl/vdae175","url":null,"abstract":"<p><strong>Background: </strong>Brain tumor needle biopsy interventions are inflicted with nondiagnostic or biased sampling in up to 25% and hemorrhage, including asymptomatic cases, in up to 60%. To identify diagnostic tissue and sites with increased microcirculation, intraoperative optical techniques have been suggested. The aim of this study was to investigate the clinical implications of in situ optical guidance in frameless navigated tumor biopsies.</p><p><strong>Methods: </strong>Real-time feedback on protoporphyrin IX (PpIX) fluorescence, microcirculation, and gray-whiteness was given before tissue sampling (272 positions) in 20 patients along 21 trajectories in total. The primary variables of investigation were fluorescence in relation to neuropathological findings and gadolinium (Gd) enhancement, increased cerebral microcirculation in relation to bleeding incidence, number of trajectories, and impact on operation time.</p><p><strong>Results: </strong>PpIX fluorescence was detected in Glioblastoma IDH-wildtype CNS WHO grade 4 (<i>n</i> = 12), Primary diffuse large B-cell lymphoma (<i>n</i> = 3), astrocytoma IDH-mutated CNS WHO grade 4 (<i>n</i> = 1) (Ki67 indices ≥ 15%). For 2 patients, no PpIX fluorescence or Gd was found, although samples contained tumorous tissue (Ki67 index 6%). Increased microcirculation was found along 9 trajectories (34 sites), located in cortical, tumorous, or tentorium regions. Postoperative bleedings (<i>n</i> = 10, nine asymptomatic) were related to skull opening or tissue sampling. This study strengthens the proposed independence from intraoperative neuropathology as PpIX fluorescence is detected. Objective real-time feedback resulted in fewer trajectories compared to previous studies indicating reduced operation time.</p><p><strong>Conclusions: </strong>The integrated optical guidance system provides real-time feedback in situ, increasing certainty and precision of diagnostic tissue before sampling during frameless brain tumor biopsies.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"6 1","pages":"vdae175"},"PeriodicalIF":3.7,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11647519/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142840565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of molecular classification on prognosis in children and adolescents with spinal ependymoma: Results from the HIT-MED database.","authors":"Lara Engertsberger, Martin Benesch, Martin Mynarek, Svenja Tonn, Denise Obrecht-Sturm, Thomas Perwein, Martina Stickan-Verfürth, Angela Funk, Beate Timmermann, Michael Bockmayr, Alicia Eckhardt, Alexander Claviez, Rolf-Dieter Kortmann, Markus J Riemenschneider, Torsten Pietsch, Brigitte Bison, Monika Warmuth-Metz, Kristian W Pajtler, Stefan Rutkowski, Ulrich Schüller","doi":"10.1093/noajnl/vdae179","DOIUrl":"10.1093/noajnl/vdae179","url":null,"abstract":"<p><strong>Background: </strong>Ependymomas of the spinal cord are rare among children and adolescents, and the individual risk of disease progression is difficult to predict. This study aims to evaluate the prognostic impact of molecular typing on pediatric spinal cord ependymomas.</p><p><strong>Methods: </strong>Eighty-three patients with spinal ependymomas ≤22 years registered in the HIT-MED database (German brain tumor registry for children, adolescents, and adults with medulloblastoma, ependymoma, pineoblastoma, and CNS-primitive neuroectodermal tumors) between 1992 and 2022 were included. Forty-seven tumors were analyzed by DNA methylation array profiling. In 6 cases, HOXB13 and MYCN proteins were detected as surrogate markers for specific methylation classes. Ten patients had <i>NF2</i>-related schwannomatosis.</p><p><strong>Results: </strong>With a median follow-up time of 4.9 years, 5- and 10-year overall survival (OS) were 100% and 86%, while 5- and 10-year progression-free survival (PFS) were 65% and 54%. Myxopapillary ependymoma (SP-MPE, <i>n</i> = 32, 63%) was the most common molecular type followed by spinal ependymoma (SP-EPN, <i>n</i> = 17, 33%) and <i>MYCN</i>-amplified ependymoma (<i>n</i> = 2, 4%). One case could not be molecularly classified, and one was reclassified as anaplastic pilocytic astrocytoma. 5-year PFS did not significantly differ between SP-MPE and SP-EPN (65% vs. 78%, <i>P</i> = .64). <i>MYCN</i>-amplification was associated with early relapses (<2.3 years) in both cases and death in one patient. Patients with SP-MPE subtype B (<i>n</i> = 9) showed a non-significant trend for better 5 years-PFS compared to subtype A (<i>n</i> = 18; 86% vs. 56%, <i>P</i> = .15). The extent of resection and WHO tumor grades significantly influenced PFS in a uni- and multivariate analysis.</p><p><strong>Conclusions: </strong>Molecular typing of pediatric spinal ependymomas aids in identifying very high-risk <i>MYCN</i>-amplified ependymomas. Further insights into the molecular heterogeneity of spinal ependymomas are needed for future clinical decision-making.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"6 1","pages":"vdae179"},"PeriodicalIF":3.7,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11662162/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142879387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiological, clinical, and molecular analyses reveal distinct subtypes of butterfly glioblastomas affecting the prognosis.","authors":"Ichiyo Shibahara, Ryota Shigeeda, Takashi Watanabe, Yasushi Orihashi, Yoko Tanihata, Kazuko Fujitani, Hajime Handa, Yuri Hyakutake, Mariko Toyoda, Madoka Inukai, Kohei Uemasu, Mitsuhiro Shinoda, Hideto Komai, Sumito Sato, Takuichiro Hide, Toshihiro Kumabe","doi":"10.1093/noajnl/vdae180","DOIUrl":"10.1093/noajnl/vdae180","url":null,"abstract":"<p><strong>Background: </strong>Glioblastoma (GB) is known for its highly invasive nature. Images of butterfly GB (bGB) often illustrate this characteristic, but the molecular background and origins of bGB remain unknown.</p><p><strong>Methods: </strong>We analyzed a cohort of 34 bGB patients from our dataset (K-cohort) and 46 bGB patients from publicly available datasets, including TCGA-GBM, CPTAC-GBM, IvyGAP, and UPENN-GBM.</p><p><strong>Results: </strong>In the K-cohort, the median age was 66 years, and molecular analyses revealed <i>TERT</i> promoter mutations in 55.9% of cases, with no cases exhibiting <i>H3F3A, HIST1H3B</i>, or <i>BRAF</i> mutations. Sequential radiological imaging from the K-cohort provided unique insights, showing one case originating in the corpus callosum (CC) and 3 cases originating in the cerebral hemisphere before developing into bGB. Multi-regional sampling supported a mutational trajectory from the hemisphere to the CC. These observations indicate the presence of 2 distinct radiological origins for bGB. Consequently, we classified cases into CC-type and Hemispheric-type based on the tumor volume ratio within the CC. This subgrouping was clinically meaningful; the CC-type is an independent poor prognostic factor for overall survival, with a hazard ratio of 1.8 (95% confidence interval 1.1-3.0, <i>P</i> = .033), and is molecularly distinct by a higher frequency of methylated <i>MGMT</i>p (<i>P</i> = .0039) compared to the Hemispheric-type.</p><p><strong>Conclusions: </strong>Our results highlight that the radiological features of bGB are not homogenous and can indicate 2 potential subtypes based on their origins. Further studies are mandatory, but CC-type and Hemispheric-type exhibit distinct clinical backgrounds, outcomes, and molecular features.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"6 1","pages":"vdae180"},"PeriodicalIF":3.7,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11647517/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142840574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A single-center case study series assessing the effect of selumetinib use in patients with neurofibromatosis-related plexiform neurofibromas.","authors":"João Passos, Marta P Soares, Duarte Salgado, Sofia Nunes, Daniela Cavaco, Pedro M Garrido, Mónica Coutinho, Inês Patrocínio Carvalho, Miguel Vilares, Mafalda Ferreira, Cristina Lacerda","doi":"10.1093/noajnl/vdae177","DOIUrl":"10.1093/noajnl/vdae177","url":null,"abstract":"<p><strong>Background: </strong>Neurofibromatosis type 1 (NF1) is a common genetic disorder of phenotypic variability with age-dependent penetrance. This study describes the diagnosis, clinical characterization, management, and outcomes of a large patient cohort with plexiform neurofibroma (PN) treated with selumetinib in a real-world clinical setting.</p><p><strong>Methods: </strong>This single-center observational study consecutively enrolled patients with NF1-PN treated with selumetinib from April 2018 to 2023. Data on clinical features, tumor types and locations, and results from genetic tests were recorded at baseline; details of disease management with selumetinib and surgical intervention and disease evolution including imaging data and evaluations of pain and function were documented.</p><p><strong>Results: </strong>Overall, 54 patients with a median age (range) of 16.4 (4.5-58.0) years were enrolled. Most had cutaneous manifestations (88.9%), including cutaneous neurofibromas and PN. Patients underwent [18F]fluorodeoxyglucose (FDG)-PET/CT imaging before treatment to rule out malignant lesions. Initial evaluations included directed magnetic resonance imaging (MRI), which facilitated future comparisons and allowed for the assessment of PN resectability. Pharmacological treatment with selumetinib (with surgery, without surgery) resulted in the following proportion of patients achieving stable disease (58.8%, 54.3%), partial response (29.4%, 28.6%), and improved pain (58.8%, 37.1%), deformity (17.6%, 20.0%), and functional (17.6%, 20.0%) outcomes, respectively.</p><p><strong>Conclusions: </strong>Results from this study demonstrate that NF1-PN can be managed effectively with selumetinib with surgical intervention in some patients. Most patients achieved tumor stability and improved symptom control, and the majority of patients continue under treatment. Effective diagnosis and management were achieved through individualized utility of FDG-PET/CT and MRI imaging and targeted resource allocation.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"6 1","pages":"vdae177"},"PeriodicalIF":3.7,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11600336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-small cell lung cancer with synchronous brain metastases: Identification of prognostic factors in a retrospective multicenter study (HOT 1701).","authors":"Yoshihito Ohhara, Tetsuya Kojima, Osamu Honjo, Noriyuki Yamada, Toshitaka Sato, Hirofumi Takahashi, Kei Takamura, Taichi Takashina, Noriaki Sukoh, Hisashi Tanaka, Yasutaka Kawai, Yuka Fujita, Keiki Yokoo, Fumihiro Hommura, Toshiyuki Harada, Ryoichi Honda, Toraji Amano, Hirotoshi Dosaka-Akita, Satoshi Oizumi, Ichiro Kinoshita","doi":"10.1093/noajnl/vdae168","DOIUrl":"10.1093/noajnl/vdae168","url":null,"abstract":"<p><strong>Background: </strong>Non-small-cell lung cancer (NSCLC) is associated with a high incidence of brain metastasis (BM), and the prognosis of patients with NSCLC and BM is poor. This study aimed to identify the prognostic factors and elucidate the survival rates of Japanese patients with NSCLC and BM at initial diagnosis.</p><p><strong>Methods: </strong>HOT 1701 is a retrospective multicenter study of patients with NSCLC and BM at initial diagnosis. The medical records of all consecutive patients diagnosed with advanced or recurrent NSCLC and BM at 14 institutions of the Hokkaido Lung Cancer Clinical Study Group Trial (HOT) in Japan were reviewed. The participants were categorized based on the presence or absence of driver mutations. The Kaplan-Meier method was used to estimate median overall survival (OS). Univariate and multivariate analyses were performed to identify prognostic factors in these patients.</p><p><strong>Results: </strong>Among 566 patients with NSCLC and BM, the median OS was 11.8 months. Patients with driver mutations survived longer than those without driver mutations. The univariate and multivariate analyses revealed 6 independent prognostic factors: age ≥65 years, poor performance status, T factor, absence of driver gene mutations, presence of extracranial metastases, and number of BM. According to the prognostic score based on these 6 factors, the patients were stratified into 3 risk groups: low-, intermediate-, and high-risk, with median OS of 27.8, 12.2, and 2.8 months, respectively.</p><p><strong>Conclusions: </strong>We developed a new prognostic model for patients with NSCLC and BM, which may help determine prognosis at diagnosis.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"6 1","pages":"vdae168"},"PeriodicalIF":3.7,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558066/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic tumor evolution dictates human medulloblastoma progression.","authors":"Yana Ruchiy, Ioanna Tsea, Efthalia Preka, Bronte Manouk Verhoeven, Thale Kristin Olsen, Shenglin Mei, Indranil Sinha, Klas Blomgren, Lena-Maria Carlson, Cecilia Dyberg, John Inge Johnsen, Ninib Baryawno","doi":"10.1093/noajnl/vdae172","DOIUrl":"10.1093/noajnl/vdae172","url":null,"abstract":"<p><strong>Background: </strong>Medulloblastoma (MB) is the most common high-grade pediatric brain tumor, comprised of 4 main molecular subgroups-sonic-hedgehog (SHH), Wnt, Group 3, and Group 4. Group 3 and Group 4 tumors are the least characterized MB subgroups, despite Group 3 having the worst prognosis (~50% survival rate), and Group 4 being the most prevalent. Such poor characterization can be attributed to high levels of inter- and intratumoral heterogeneity, making it difficult to identify common therapeutic targets.</p><p><strong>Methods: </strong>In this study, we generated single-cell sequencing data from 14 MB patients spanning all subgroups that we complemented with publicly available single-cell data from Group 3 patients. We used a ligand-receptor analysis tool (CellChat), expression- and allele-based copy-number variation (CNV) detection methods, and RNA velocity analysis to characterize tumor cell-cell interactions, established a connection between CNVs and temporal tumor progression, and unraveled tumor evolution.</p><p><strong>Results: </strong>We show that MB tumor cells follow a temporal trajectory from those with low CNV levels to those with high CNV levels, allowing us to identify early and late markers for SHH, Group 3, and Group 4 MBs. Our study also identifies <i>SOX4</i> upregulation as a major event in later tumor clones for Group 3 and Group 4 MBs, suggesting it as a potential therapeutic target for both subgroups.</p><p><strong>Conclusion: </strong>Taken together, our findings highlight MB's inherent tumor heterogeneity and offer promising insights into potential drivers of MB tumor evolution particularly in Group 3 and Group 4 MBs.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"6 1","pages":"vdae172"},"PeriodicalIF":3.7,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11629688/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142808959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biological and prognostic relevance of epigenetic regulatory genes in high-grade gliomas.","authors":"Sonikpreet Aulakh, Joanne Xiu, Andrew Hinton, Sourat Darabi, Michael J Demeure, Soma Sengupta, Santosh Kesari, David M Ashley, Ashley Love Sumrall, Michael J Glantz, David Spetzler","doi":"10.1093/noajnl/vdae169","DOIUrl":"10.1093/noajnl/vdae169","url":null,"abstract":"<p><strong>Background: </strong>High-grade gliomas (HGGs) are the most aggressive type of gliomas and have the poorest outcomes. Chromatin remodeling (CR) genes have been implicated in multiple oncogenic pathways in numerous cancer types. In gliomagenesis, CR genes have been implicated in regulating the stemness of glioma cells, the tumor microenvironment (TME), and resistance to therapies.</p><p><strong>Methods: </strong>We performed molecular profiling of 4244 HGGs and evaluated associations of CR mutations with other cancer-related biomarkers, infiltration by immune cells, and immune gene expression. We also evaluated the association between CR mutations and survival in wild-type <i>IDH</i> HGG patients.</p><p><strong>Results: </strong>Nearly 10% of HGGs carry mutations in CR genes, with a higher prevalence (15%) in HGGs with <i>IDH</i> mutations. Analysis of cooccurrence with other biomarkers revealed that CR-mutated HGGs possess favorable genetic alterations which may have prognostic value. CR-mutated HGGs with wild-type <i>IDH</i> demonstrated colder TME and worse OS overall compared to the CR-wild-type HGGs.</p><p><strong>Conclusions: </strong>Our study reveals the prognostic effects of CR mutations in HGG and points to several biomarker candidates that could suggest sensitivity to emerging therapeutic strategies.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"6 1","pages":"vdae169"},"PeriodicalIF":3.7,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11565242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142649819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of the pediatric neuro-oncology services assessment aid: An assessment tool for pediatric neuro-oncology service delivery capacity.","authors":"Revathi Rajagopal, Rosdali Diaz Coronado, Syed Ahmer Hamid, Regina Navarro Martin Del Campo, Frederick Boop, Asim Bag, Alma Edith Benito Reséndiz, Vasudeva Bhat K, Danny Campos, Kenneth Chang, Ramona Cirt, Ludi Dhyani Rahmartani, Jen Chun Foo, Julieta Hoveyan, John T Lucas, Thandeka Ngcana, Rahat Ul Ain, Nuha Omran, Diana S Osorio, Bilal Mazhar Qureshi, Noah D Sabin, Ernestina Schandorf, Patrick Bankah, Mary-Ann Dadzie, Hafisatu Gbadamos, Hend Sharafeldin, Mahendra Somathilaka, Peiyi Yang, Yao Atteby Jean-Jacques, Anan Zhang, Zeena Salman, Miriam Gonzalez, Paola Friedrich, Carlos Rodriguez-Galindo, Ibrahim Qaddoumi, Daniel C Moreira","doi":"10.1093/noajnl/vdae171","DOIUrl":"https://doi.org/10.1093/noajnl/vdae171","url":null,"abstract":"<p><strong>Background: </strong>To enhance the quality of care available for children with central nervous system (CNS) tumors across the world, a systematic evaluation of capacity is needed to identify gaps and prioritize interventions. To that end, we created the pediatric neuro-oncology (PNO) resource assessment aid (PANORAMA) tool.</p><p><strong>Methods: </strong>The development of PANORAMA encompassed 3 phases: operationalization, consensus building, and piloting. PANORAMA aimed to capture the elements of the PNO care continuum through domains with weighted assessments reflecting their importance. Responses were ordinally scored to reflect the level of satisfaction. PANORAMA was revised based on feedback at various phases to improve its relevance, usability, and clarity.</p><p><strong>Results: </strong>The operationalization phase identified 14 domains by using 252 questions. The consensus phase involved 15 experts (6 pediatric oncologists, 3 radiation oncologists, 2 neurosurgeons, 2 radiologists, and 2 pathologists). The consensus phase validated the identified domains, questions, and scoring methodology. The PANORAMA domains included national context, hospital infrastructure, organization and service integration, human resources, financing, laboratory, neurosurgery, diagnostic imaging, pathology, chemotherapy, radiotherapy, supportive care, and patient outcomes. PANORAMA was piloted at 13 institutions in 12 countries, representing diverse patient care contexts. Face validity was assessed by examining the correlation between the estimated score by respondents and calculated PANORAMA scores for each domain (<i>r</i> = 0.67, <i>P</i> < .0001).</p><p><strong>Conclusions: </strong>PANORAMA was developed through a systematic, collaborative approach, ensuring its relevance to evaluate core elements of PNO service capacity. Distribution of PANORAMA will enable quantitative service evaluations across institutions, facilitating benchmarking and the prioritization of interventions.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"6 1","pages":"vdae171"},"PeriodicalIF":3.7,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555432/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of antibiotic drug use on outcome and therapy-related toxicity in patients with glioblastoma-A retrospective cohort study.","authors":"Linda Götz, Tananeh Ansafi, Michael Gerken, Monika Klinkhammer-Schalke, Anna Fischl, Markus J Riemenschneider, Martin Proescholdt, Elisabeth Bumes, Oliver Kölbl, Nils Ole Schmidt, Ralf Linker, Peter Hau, Tareq M Haedenkamp","doi":"10.1093/noajnl/vdae170","DOIUrl":"10.1093/noajnl/vdae170","url":null,"abstract":"<p><strong>Background: </strong>Glioblastoma (GB) is the most frequent malignant brain tumor and has a dismal prognosis. In other cancers, antibiotic use has been associated with severity of chemotherapy-induced toxicity and outcome. We investigated if these mechanisms are also involved in GB.</p><p><strong>Methods: </strong>We selected a cohort of 78 GB patients who received combined radiochemotherapy. We investigated if exposure to prediagnostic antibiotic use is associated with clinical side effects and laboratory changes during adjuvant therapy as well as overall survival (OS) and progression-free survival (PFS) using chi-square test, binary logistic regression, Kaplan-Meyer analysis, and multivariable Cox regression.</p><p><strong>Results: </strong>Seventeen patients (21.8%) received at least one course of prediagnostic antibiotics and 61 (78.2%) received no antibiotics. We found a higher incidence of loss of appetite (23.5% vs. 4.9%; <i>P</i> = .018) and myelosuppression (41.2% vs. 18.0%; <i>P</i> = .045) in the antibiotic group. Multivariable logistic regression analysis revealed antibiotics to be a predictor for nausea (OR = 6.94, 95% CI: 1.09-44.30; <i>P</i> = .041) and myelosuppression (OR = 9.75, 95% CI: 1.55-61.18; <i>P</i> = .015). Furthermore, lymphocytopenia was more frequent in the antibiotic group (90.0% vs. 56.1%, <i>P</i> = .033). There were no significant differences in OS (<i>P</i> = .404) and PFS (<i>P</i> = .844). Multivariable Cox regression showed a trend toward shorter survival time (<i>P</i> = .089) in the antibiotic group.</p><p><strong>Conclusions: </strong>Our study suggests that antibiotic use affects symptoms and lab values in GB patients. Larger prospective studies are required to investigate if prediagnostic antibiotic use could be a prognostic factor in GB patients.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"6 1","pages":"vdae170"},"PeriodicalIF":3.7,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528512/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Effect of bevacizumab on refractory meningiomas: 3D volumetric growth rate versus response assessment in neuro-oncology criteria.","authors":"","doi":"10.1093/noajnl/vdae164","DOIUrl":"https://doi.org/10.1093/noajnl/vdae164","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1093/noajnl/vdae128.].</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"6 1","pages":"vdae164"},"PeriodicalIF":3.7,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11450400/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142383056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}